Conclusion: The Future of Single-Isomer Pharmacology

By Jerrold F. Rosenbaum, MD

Taken together, the articles gathered in this supplement underscore the major role in drug development that single-isomer science can play—a role that will undoubtedly take on a greater importance in the future. While the chirality of certain pharmacologically active molecules has been recognized for almost a century, it is only in recent years that drug synthesis and chiral separation techniques have advanced far enough to allow meaningful comparisons among enantiomers. Now that these methods are broadly available, the potential applications of single isomer drug development are considerable.

Numerous examples from a range of therapeutic areas confirm that single enantiomers can enhance clinical efficacy, reduce adverse effects, cause fewer interactions with other drugs, and minimize response variations among patients by offering more predictable pharmacokinetics and greater selectivity. In some cases, these advantages are simply due to the removal of an inactive enantiomer, but in other cases, a given dose of a single isomer offers greater benefits when administered alone than when administered as the racemic mixture, suggesting that the opposite enantiomer (the dis- tomer) actually has detracting effects. As the papers by Drs. Gal and Hutt explain, the different activities of a pair of enantiomers are usually traceable to stereochemical differences in the way they interact with chiral macromolecules such as enzymes, transport systems, and receptors.

Drs. Flockhart and Nelson illustrate these principles in their review of esomeprazole in the management of peptic ulcers and levodopa in the treatment of allergic asthma. Esomeprazole offers greater bioavailability than its racemate, omeprazole, and hence produces greater and more prolonged suppression of gastric acid secretion. Similarly, many of the adverse effects of racemic albuterol have been traced to the S-enantiomer, and removing it from the racemic mixture significantly reduces airway hyperreactivity and the need for rescue medications.

Dr. Gal shows how chiral science is being used today to develop improved treatments for gastrointestinal motility disorders, anxiety, dyslipidemia, bacterial and fungal infections, epilepsy, and cancer. As described by Drs. DeVane and Boulton, these principles are also relevant to the clinical use of antidepressants. Some of the widely prescribed agents in this class exist as racemic mixtures, but adverse effects or drug interactions attributable to one of the enantiomers may hamper their utility. The distomers, for example, may have little or no antidepressant activity, and their presence may complicate pharmacokinetic and pharmacodynamic mechanisms.

These findings are now known to be relevant to escitalopram, the S-enantiomer of the selective serotonin reuptake inhibitor citalopram. Escitalopram is the most serotonin-selective compound in its class and is ~30-fold more potent than (R)-citalopram. As reviewed by Drs. Owens, Rosenbaum, and Gorman in their respective articles, clinical trials comparing escitalopram (10–20 mg/day) and citalopram (20–40 mg/day) show that both drugs significantly improve symptoms of depression and anxiety relative to placebo, and that overall response rates are higher with both compounds than with placebo. However, escitalopram’s actions are clinically apparent after just 1 week of treatment, whereas citalopram does not begin to differ from placebo until 4 to 6 weeks after treatment is initiated. Furthermore, escitalopram is significantly superior to citalopram at several time points, suggesting that it has not only a faster onset of action, but also a greater overall effect than citalopram in controlling depression and associated anxiety.

In summary, the isolation and development of single isomers has advanced the safety and efficacy of a broad range of drugs, and will continue to do so. However, much remains to be learned, and it is clear that not all single isomers will have advantages as predicted by their more specific pharmacodynamic characteristics. For example, sotalol consists of two enantiomers that are both potassium channel antagonists and therefore act as class III antiarrhythmic drugs. One of these enantiomers has β-blocking activity while the other, desxotolol, has almost none. Desxotolol was therefore investigated as a possibly superior antiarrhythmic agent. However, it was abandoned because of unexpectedly high cardiac mortality rates, which are now thought to reflect a protective quality of the racemate’s β-blockade. This highlights the need for continued basic and clinical research to unravel these complexities and better predict which single enantiomers will yield treatment benefits.

Several single-isomer drugs offer important advantages in enhanced therapeutic efficacy at equal or lower doses, reduced side effects and drug interactions, and clearer relationships between drug concentration and effect. These enhancements offer clinicians the opportunity to treat their patients more safely and effectively, thereby minimizing the personal and financial costs associated with high doses, side effects, and repeat office visits. Single isomers represent a step forward in the search for better, safer, and more cost-effective drugs, and chiral science will play an increasingly important role in future medical advances. 

---

Dr. Rosenbaum is chief of psychiatry at Massachusetts General Hospital (MGH), president and executive director of the MGH Mood and Anxiety Disorders Institute, and professor of psychiatry at Harvard Medical School, both in Boston.

Disclosure: Dr. Rosenbaum has served on the advisory board for Cyberonics, Novartis, Organon, Eli Lilly, Forest Laboratories, and Wyeth-Ayerst.

April 2002 55 MedWorks Media
The Biological and Clinical Significance of Single Isomers

6 Participant Biographies

8 Single-Isomer Science: The Phenomenon and Its Terminology
   By Joseph Gal, PhD

14 The Development of Single-Isomer Molecules: Why and How
   By Andrew J. Hutt, PhD

23 Single Isomer Versus Racemate: Is There a Difference?
   Clinical Comparisons in Allergy and Gastroenterology
   By David A. Flockhart, MD, PhD, and Harold S. Nelson, MD

28 Great Expectations in Stereochemistry: Focus on Antidepressants
   By C. Lindsay DeVane, PharmD, and David W. Boulton, PhD

34 Escitalopram: A Second-Generation SSRI
   By Michael J. Owens, PhD, and Jerrold F. Rosenbaum, MD

40 Efficacy Comparison of Escitalopram and Citalopram in the Treatment
   of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials
   By Jack M. Gorman, MD, Andrew Korotzer, PhD, and Guojin Su, PhD

45 New Single-Isomer Compounds on the Horizon
   By Joseph Gal, PhD

55 Conclusion: The Future of Single-Isomer Pharmacology
   By Jerrold F. Rosenbaum, MD
Mental Fitness Board of Advisors

Editor
Kimberly Ann Yonkers, MD
Yale University Medical School
New Haven, CT

Board of Advisors, Psychiatry
P. Munir Doraiswamy, MD
Duke University Medical Center
Durham, NC
Jack M. Gorman, MD
Columbia University College of Physicians & Surgeons
New York, NY
Robert Hirschfeld, MD
University of Texas Medical School
Galveston, TX
Prakash S. Manand, MD
Duke University Medical Center
Durham, NC
Charles B. Nemeroff, MD, PhD
Emory University School of Medicine
Atlanta, GA
Alan Schatzberg, MD
Stanford University School of Medicine
Stanford, CA
Andrew Slaby, MD
NYU School of Medicine
New York Medical College
New York, NY
Myrna M. Weissman, PhD
Columbia University College of Physicians & Surgeons
New York, NY
Joseph Zohar, MD
Chaim Sheba Medical Center
Tel Hashomer, Israel

Board of Advisors, Primary Care & Integrated Medicine
Roger O. Kothari, MD
University of Iowa Hospital
Iowa City, IA

Board of Advisors, Obstetrics & Gynecology
Georgia Witkin, PhD
Mount Sinai School of Medicine
New York, NY

Consumer Advocacy Board
Miriama Biddulph, CSW
Columbia-Presbyterian Medical Center
New York, NY
Ms. Laurie Flynn
National Alliance for the Mentally Ill
Arlington, VA
Herbert Hendin, MD
American Foundation for Suicide Prevention
New York, NY
Peter Kramer, MD
Brown University Medical School
Providence, RI
Ms. Lydia Lewis
National Depressive and Manic-Depressive Association
Chicago, IL
Ms. Constance Lieber
National Alliance for Research on Schizophrenia and Depression
Great Neck, NY
Mitchell Rosenthal, MD
Phoenix House
New York, NY
Ms. Jamie Talan
Newsday
New York, NY
Mrs. Mary Wallace
New York, NY

Executive Editors, Consumer Edition
Jan A. Fawcett, MD
Rush Institute for Mental Well-Being
Chicago, IL
Norman Sussman, MD
NYU School of Medicine
New York, NY

CME Director
Mr. Irving Gerler
Mount Sinai School of Medicine
New York, NY

Vice Presidents and Associate Publishers
Imre Balanli
Genevieve Romano
Managing Editor
Christopher Nacarati
Senior Editor, International
Amanda Schoenberg
Deputy Editors
Susan Curry
Deborah Hughes
José R. Ralph
CME Projects Editor
Kathrin Wiltfang
Senior Acquisitions Editor
Caroline Carlin Risman
Acquisitions Editor
Lisa Arrington
Production Coordinator
Lila Moses
Assistant to the Publisher
Lowell Taeiger
Art Direction & Design
Anthony J. Korsak
Designer, Multimedia
Michael Mosley
Administrative Assistant
Claudette Crawford
Controller
John Spano
Contributing Editor
Claire Roberts

Contributing Writers
David W. Bouton, PhD
C. Lindsay DeVane, PharmD
David A. Flockhart, MD, PhD
Joseph Gal, PhD
Jack M. Gorman, MD
Andrew J. Hutt, PhD
Andrew Korotzer, PhD
Harold S. Nelson, MD
Michael J. Owens, PhD
Jerrold F. Rosenbaum, MD
Guojin Su, PhD

Corporation Counsel
Kevin F. Suer, Esq.
Davis, Wright & Tremaine

Director of Advertising Sales
Darren L. Brodeur
Director, Oncology Sales
Paul McDaniel
Associate Sales Manager—Latin America
James Kassaris

Founder & Publisher
James M. La Rossa Jr.
DISCLAIMER
This academic supplement is provided as a service to medicine by Forest Pharmaceuticals. Sponsorship of this review does not imply the sponsor's agreement with the views expressed herein.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher, the sponsor, nor the authors can be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound currently under clinical investigation.

Copyright ©2002, MedWorks Media, LLC. 333 Hudson St., New York, NY 10013.
Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form.